For more than 80 years, our company has played a significant role in the discovery and development of novel medicines and vaccines to treat and prevent infectious diseases.
In addition to a combined portfolio of vaccines, antibiotic and antifungal medicines, and medicines for HIV and hepatitis C (HCV), we have multiple programs that span discovery through late-stage development.
According to the World Health Organization (WHO), every year, there are approximately 5.5 million deaths worldwide caused by infectious and/or parasitic diseases. We have a long history of both in-house research and engagement with external partners to address infectious diseases, and we continue to seek new ways in which we can contribute expertise and resources to these disease areas.
We apply our research and development resources, expertise and technology to identifying potential products that would address unmet needs in the treatment of infectious diseases, such as HIV, HCV and bacterial infections. We are also involved in a number of product-development partnerships and research collaborations to further develop treatments to address those diseases, as well as neglected tropical diseases (NTDs) and tuberculosis (TB).
We recognize that new methods and a broader scope of collaborating—with both public and private entities—are critical to continuing innovation. This is true for all diseases, and especially true for diseases prevalent in low- and middle-income countries, for which the relevant expertise spans academia, local public health authorities, industry and international agencies. We plan to continue to expand our interactions with these groups to provide relevant expertise and resources.
We also recognize that our research capabilities and our access strategies play an important role in recruiting outstanding scientists as well as potential external research collaborators seeking to make the products developed from their discoveries available to patients worldwide.